Table 2. Demographic characteristics of NSCLC patients with first-onset MPE receiving PET/CT examination.
| Parameters | Actionable mutation (+) (n=58) | Actionable mutation (−) (n=45) | Total (n=103) |
|---|---|---|---|
| Age (years) | 60 [51–68] | 68 [58–75] | 65 [23–89] |
| Gender | |||
| Male | 26 (44.8) | 33 (73.3) | 59 (57.3) |
| Female | 32 (55.2) | 12 (26.7) | 44 (42.7) |
| ECOG PS | |||
| 0–1 | 56 (96.6) | 38 (84.4) | 94 (91.3) |
| ≥2 | 2 (3.4) | 7 (15.6) | 9 (8.7) |
| Histological type | |||
| Adenocarcinoma | 58 (100.0) | 36 (80.0) | 94 (91.3) |
| Non-adenocarcinoma | 0 (0.0) | 9 (20.0) | 9 (8.7) |
| Contralateral lung metastases | |||
| No | 50 (86.2) | 42 (93.3) | 92 (89.3) |
| Yes | 8 (13.8) | 3 (6.7) | 11 (10.7) |
| Bone metastases | |||
| No | 35 (60.3) | 31 (68.9) | 66 (64.1) |
| Yes | 23 (39.7) | 14 (31.1) | 37 (35.9) |
| Liver metastases | |||
| No | 53 (91.4) | 40 (88.9) | 93 (90.3) |
| Yes | 5 (8.6) | 5 (11.1) | 10 (9.7) |
| Brain metastases | |||
| No | 51 (87.9) | 41 (91.1) | 92 (89.3) |
| Yes | 7 (12.1) | 4 (8.9) | 11 (10.7) |
| Adrenal gland metastases | |||
| No | 53 (91.4) | 40 (88.9) | 93 (90.3) |
| Yes | 5 (8.6) | 5 (11.1) | 10 (9.7) |
| Stage | |||
| IVA | 25 (43.1) | 24 (53.3) | 49 (47.6) |
| IVB | 33 (56.9) | 21 (46.7) | 54 (52.4) |
| Systemic treatment within 30 days | |||
| Mut (−)—chemotherapy | 0 (0.0) | 30 (66.7) | 30 (29.1) |
| Mut (+)—targeted therapy | 58 (100.0) | 0 (0.0) | 58 (56.3) |
| Mut (−)—immunotherapy | 0 (0.0) | 15 (33.3) | 15 (14.6) |
| MPE control measures within 30 days | |||
| Intrapleural perfusion | 39 (67.9) | 23 (51.1) | 62 (60.2) |
| Indwelling pleural catheter | 44 (84.6) | 31 (68.9) | 75 (80.6) |
| First MPE recurrence requiring drainage | |||
| Recurrence within 100 days | 8 (13.8) | 22 (48.9) | 30 (29.1) |
| Recurrence within 300 days | 15 (25.9) | 25 (55.6) | 40 (38.8) |
| Recurrence | 27 (46.6) | 32 (71.1) | 59 (57.3) |
Data are presented as median [interquartile range] or n (%). NSCLC, non-small cell lung cancer; MPE, malignant pleural effusion; PET/CT, positron emission tomography/computed tomography; ECOG PS, Eastern Cooperative Oncology Group performance status; mut, actionable mutation.